ROIVANT SCIENCES LTD (ROIV)

BMG762791017 - Common Stock

10.765  +0.2 (+1.84%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ROIVANT SCIENCES LTD

NASDAQ:ROIV (6/12/2024, 9:29:09 AM)

10.765

+0.2 (+1.84%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-5.29%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap7.95B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ROIV Daily chart

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The firm advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Company Info

ROIVANT SCIENCES LTD

11-12 St. James's Square, Suite 1, 3rd Floor

London

P: 442074003347.0

Employees: 904

Website: http://roivant.com/

ROIV News

News Image13 days ago - Market News VideoRoivant Sciences (ROIV) Shares Cross Below 200 DMA
News Image13 days ago - BusinessInsiderROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Roivant Sciences (NASDAQ:ROIV) just reported results for the fourth quarter of ...

News Image13 days ago - InvestorPlaceROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024

ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

News Image13 days ago - Roivant SciencesRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
News Image13 days ago - Roivant SciencesRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth...

News Imagea month ago - Roivant SciencesRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

ROIV Twits

Here you can normally see the latest stock twits on ROIV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example